EBS earnings

First Quarter 2026 Total Revenues of $156.1 millionFirst Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4%First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 31, 2026. "Emergent's first quarter results demonstrate a strong and positive start to 2026, with healthy topline revenue of $156 million, above the high-end of our guidance range, and adjusted EBITDA of $36 million," said Joe Papa, president and CEO of Emergent. "We are further strengthening our financial position in 202

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can b

Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of

GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior yearThird Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38%Raising the Full Year 2025 Revenue and Profitability GuidanceStrong Sequential Naloxone Revenue Growth, Primarily Driven by NARCAN® Nasal Spray, QoQ Through Q3 2025 GAITHERSBURG, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results

GAITHERSBURG, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, October 29, 2025, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can b

Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 millionSecond Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior yearSecond Quarter 2025 Gross Margin % of 36% and Adjusted Gross Margin % of 49%, an expansion of 6,200 bps and 2,300 bps, respectively, versus prior yearSecond Quarter 2025 Adjusted EBITDA of $28.5 million, an increase of 382% versus prior yearSecond Quarter 2025 Adjusted EBITDA Margin of 20% of Total Revenues, an improvement of 2,400 bps versus prior yearRaising the low end/midpoint of Full Year 2025 Profitability Guidance GAITHERSBURG, Md., Aug. 06, 2025 (GLOBE NE

GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be

First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 

GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025. Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be a

Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in Net Loss of 37% versus prior yearFourth Quarter 2024 Adjusted EBITDA of $21.0 million, increase of 518% versus prior yearFull Year 2024 Adjusted EBITDA of $183.1 million, compares favorably to a loss of $22.3 million in 2023Guiding to 2025 Adjusted EBITDA of $150 - $200 million and improved gross margins GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the quarter and year ended December 31, 2024. "As we close out 2024, I'm proud to share we delivered f

GAITHERSBURG, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Monday, March 3, 2025, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2024. Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the cal

Third Quarter 2024 Total Revenues of $293.8 million, increase of 9% versus prior yearThird Quarter 2024 Net Income of $114.8 million, increase of 144% versus prior yearThird Quarter 2024 Adjusted EBITDA of $105.3 million, increase of 432% versus prior yearRaises FY 2024 guidance GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the third quarter ended September 30, 2024. "Through disciplined execution and steady, measurable progress, Emergent's financial position is the strongest it has been since 2021 as evidenced by our favorable third-quarter results," said CEO Joe Papa. "We have successfully improved effici

GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024. Webcast & Conference Call InformationParticipants can access the conference call live via webcast. To join via telephone, please use the following dial-in details: U.S. / New York: +1-646-968-2525U.S. & Canada (Toll Free): +1-888-596-4144Conference ID: 5259189 A replay of the call can be accessed from the Investors page of Emergent's website. About Emergent BioSolutionsAt Emergent

Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance rangeSecond Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) millionUpdates FY 2024 guidance GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the second quarter ended June 30, 2024. "In the first half of the year, we made great progress to stabilize our financial position by strategically divesting assets, resolving several legacy issues, and securing operational cash flow and working capital improvements," said Joe Papa, president and CEO at Emergent. "As a result, we ex

GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of 2024, as well as full year guidance. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that

First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products," said Joe Papa, President and CEO at Emergent. "We also took significant actions to improve our debt position, reduce operating expenses and strengthen our financial flexibility. Emergent's transformation will not happen overnight. The actions we

Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficientlyReorganization will align with evolving business goals, strategic priorities and new operational planOverall efforts expected to deliver annual cost savings of approximately $80 million  GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its enterprise workforce to improve the performance and profitability of its business. Emergent will continue to focus on its c

GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has entered into a "Consent, Waiver and Seventh Amendment" to its existing credit facility. "In light of this amendment, Emergent now has an extended runway to execute on our go-forward business plan to stabilize our financial position," stated Joe Papa, president and CEO of Emergent. "Our bank group continues to work with our management team in a constructive fashion, evidenced by this positive development." On May 1, 2024, Emergent will report its first quarter 2024 financial results via conference call, as well highlight key business updates, Q1 2024 financial review, and FY 2

GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registr

Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidanceFull Year 2023 Total Revenues of $1.05 billion, which was the mid-point of guidanceFourth Quarter 2023 Net Loss of $50 million and Adjusted EBITDA of $3 millionIssues Q1 2024 and FY 2024 guidance GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the quarter and year ended December 31, 2023. "Emergent has a long history of helping protect people around the world from opioid overdose emergencies and chemical, biological and radiological threats. This commitment to public health, together with Emergent'

GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent's newly appointed president and CEO, Joseph C. Papa, will provide remarks. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along w

Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of  $(266)M and Adjusted EBITDA(2) of $20MUpdates FY 2023 guidance GAITHERSBURG, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported selected financial results for the third quarter ended September 30, 2023. The selected financial results reported include limited third quarter and year-to-date results, as well as selected balance sheet and cash flow information. As part of our quarterly review process, the Company determined that its state deferred tax liability was overstated as of December 31, 2022, resulting in an understatement of the inco

GAITHERSBURG, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023. The call will no longer take place on November 2, 2023. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference cal

GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode

Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56MUpdates FY 2023 guidance and provides initial Q3 2023 forecast for total revenues GAITHERSBURG, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the second quarter ended June 30, 2023. It also announced strategic steps to reduce investment in and de-emphasize focus on growth in its CDMO business. "Emergent has achieved a number of strategic milestones in 2023 that will help America be better prepared to face future public health threats and help to strengthen Emergent's financial position," said interim Chie

Actions bring sharpened focus on MCM and NARCAN® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost savings over $100 million annually GAITHERSBURG, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it is reducing investment in and de-emphasizing focus on growth in its CDMO services business. As a result, Emergent is reducing operations at its Bayview facility in Baltimore, Maryland. Additionally, Emergent will reduce operations at its facility in Canton, Massachusetts, in response to changes in the volume of U.S. government procurements of medical countermeasures. This action will also result in a small

GAITHERSBURG, Md., July 25, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Tuesday, August 8, 2023, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2023, recent business developments, revenue guidance for the third quarter of 2023, and financial outlook for full year 2023. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including th

Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101MUpdates FY 2023 guidance and provides initial Q2 2023 guidance GAITHERSBURG, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 31, 2023. Among the highlights, Emergent has received from the U.S. government Notices of Intent to Purchase medical countermeasures to combat smallpox and botulism. Further, the Company expects to reach a deal with its lenders to amend and extend the terms of its debt obligations. "Since the beginning of the year, we have taken strategic actions

GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second quarter of 2023, and financial outlook for full year 2023. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including th

Reports Q4 2022 total revenues of $331M resulting in FY 2022 total revenues of $1,121M, in line with prior guidanceReports Q4 2022 net loss of $88M and FY 2022 net loss of $224MReports Q4 2022 adjusted EBITDA of $34M and FY 2022 adjusted EBITDA of $26M, in line with prior guidanceReports Q4 2022 adjusted gross margin of 48% and FY 2022 adjusted gross margin of 41%For FY 2023, expects continued stability of revenues and further improvements in operations and normalizing of cost structure leading to guidance of total revenues of $1,150M, adjusted EBITDA of $100M, and adjusted gross margin of 43%, all at the midpoint GAITHERSBURG, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolution

Adds two revenue-generating vaccines for the prevention of cholera and typhoid fever that will establish Bavarian Nordic as a global leader in travel vaccinesBroadens development pipeline with a late-stage Chikungunya vaccine candidate with significant synergistic market opportunity in areas with a high unmet medical needExpands manufacturing footprint and flexibility with facility in Switzerland and adds research competences with facility in San Diego, CATotal acquisition price of up to USD 380 million, including an upfront payment of USD 270 millionConference call today at 2:00 PM CET COPENHAGEN, Denmark, February 15, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has ent

GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a total value of up to $380 million, including potential future milestone payments. Under the terms of the definitive agreement, Bavarian Nordic will acquire the rights to VIVOTIF®, indicated for the active immunization to prevent typhoid fever, and VAXCHORA®, indicated for the active immunization to prevent cholera, as well as the development-stage chikungunya vaccine candidate CHIKV VLP. Bavarian Nordic will also acquire Emergent's manufacturing site in Bern, Switzerland, and developme

GAITHERSBURG, Md., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Monday, February 27, 2023, at 5:00 pm eastern time to discuss the financial results for the fourth quarter of 2022, recent business developments, and financial outlook for full year 2023. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode

Announces Preliminary 2022 Financial Results GAITHERSBURG, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced a sharpened strategic focus on protecting and enhancing life through its core businesses, consisting of medical countermeasures (MCM) and commercial products, including NARCAN® (naloxone HCl) Nasal Spray, as well as contract development and manufacturing (CDMO) services. Strategic developments include: The appointment of Paul Williams, Emergent's current SVP government/MCM business, as Senior Vice President, Products Business to lead the company's MCM and commercial products business, including NARCAN® Nasal Spray. Paul will report directl

GAITHERSBURG, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the third quarter ended September 30, 2022. "For more than 20 years, Emergent has been a dependable partner to customers, including the U.S. and allied governments, in helping prepare for public health threats through our products, services, and development programs," said Robert G. Kramer, president and CEO. "As we continue to strengthen our operations, be guided by financial discipline, and evaluate opportunities for growth, we remain confident in our ability to deliver results for our patients, customers, and shareholders." FINANCIAL HIGHLIGHTS (1) ($ in mill

GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2022, recent business developments, and financial outlook for full year 2022. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode a

Reports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services segmentResumes financial guidance; provides update to full year 2022 outlook GAITHERSBURG, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the second quarter ended June 30, 2022. "Central to Emergent's mission - to protect and enhance life - is our ability to provide quality products and services for the benefit of our patients and customers," said Robert G. Kramer, president and CEO of Emergent BioSolutions. "We continue to focus on combating critical public health threats with our c

GAITHERSBURG, Md., July 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2022, recent business developments, revenue guidance for the third quarter of 2022, and financial outlook for full year 2022. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the

Reports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36MTemporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements GAITHERSBURG, Md., April 28, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 31, 2022. "Emergent remains focused on our strategic plan to grow within public health threat markets where we can positively impact patients and customers," said Robert G. Kramer, president and CEO of Emergent BioSolutions. "Our diversified business model, disciplined operating approach, and financial strength enable us to continue pursuing our vision

GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for the second quarter of 2022, and financial outlook for full year 2022. This conference call can be accessed live by telephone or by webcast: Teleconference Information:Dial in number – toll-free: (855) 766-6521Dial in number – toll: (262) 912-6157Conference ID: 3691528 Webcast Information:Visit https://edge.media-server.com/mmc/p/84272zeqfor the live webcast. A replay of the call can be acces

Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of $518M, in line with prior guidanceUpdates full year 2022 guidance; provides guidance on Q1 2022 total revenues GAITHERSBURG, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the fourth quarter and year ended December 31, 2021. "Emergent's performance in 2021 is a testament to our strategic focus and highly capable team," said Robert G. Kramer, president and CEO of Emergent BioSolutions. "Looking forward, I am encouraged by the stability and durability of our diversified business lines an

GAITHERSBURG, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the financial results for the fourth quarter 2021, recent business developments, financial outlook for full year 2022, and revenue guidance for the first quarter of 2022. This conference call can be accessed live by telephone or by webcast: Teleconference Information:Dial in number – toll-free: (855) 766-6521Dial in number – toll: (262) 912-6157Conference ID: 7619558 Webcast Information:Visit https://edge.media-server.com/mmc/p/tfd93ojy for the live webcast. A replay of the call can be accessed from the

GAITHERSBURG, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the third quarter ended September 30, 2021. "Emergent's core products and service businesses remain strong as evidenced by our accomplishments this quarter," said Robert G. Kramer, president and CEO of Emergent BioSolutions. "We have secured renewals of multiple medical countermeasure supply contracts, made pipeline advancements, implemented organizational enhancements that better serve our customers, and are pursuing new business prospects. We are confident in our 2024 growth plan and remain focused on our mission - to protect and enhance life." FINANCIAL HIGHL

GAITHERSBURG, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the financial results for the third quarter of 2021, recent business developments, and financial outlook for full year 2021. This conference call can be accessed live by telephone or by webcast: eleconference Information:Dial in number – toll-free: (855) 766-6521Dial in number – toll: (262) 912-6157Conference ID: 2937668 Webcast Information:Visit https://edge.media-server.com/mmc/p/nitqgk48 for the live webcast. A replay of the call can be accessed from the Emergent website. Investor Contact:Ab

Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the second quarter ended June 30, 2021. "Our second quarter performance demonstrates the strength of our strategy and diversified business model," said Robert G. Kramer, president and chief executive officer of Emergent BioSolutions. "Through continued investment and innovation, we will play an important role in helping deliver solutions to the public health threats we face. We are proud to be resuming production of COVID-19 vaccine batches following additional reviews and collaboration with the Food and

Revises 2021 Financial Forecast GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the quarter ended March 31, 2021. FINANCIAL HIGHLIGHTS (1) (in millions)Q1 2021Q1 2020% ChangeTotal revenues$343.0$192.578%Net income (loss)$69.7($12.5)*Net income (loss) per diluted share$1.28($0.24)*Adjusted net income (2)$83.6$0.3*Adjusted net income (2) per diluted share$1.53$0.01*Adjusted EBITDA (2)$123.5$15.3** % change is greater than 100% 2021 FINANCIAL PERFORMANCE (1) (I)  Quarter Ended March 31, 2021 (Q1)  Revenues (in millions)Q1 2021Q1 2020% ChangeProduct sales, net (5):•   NARCAN® Nasal Spray$74.2$72.23%•   Anthrax

Reports record fourth quarter and year to date 2020 performance, in line with prior guidanceReaffirms full year 2021 forecast GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2020. The Company also reaffirmed its full year 2021 forecast. “Emergent’s financial and operational performance in 2020 reflects the impact we are making in addressing the growing public health threat landscape and meeting our mission to protect and enhance the lives of patients,” said Robert G. Kramer, president and CEO of Emergent BioSolutions. “We look forward to con